ReviewJournal of hematology & oncology2015

Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia.

Jingjing Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.